Demaerschalk Bart M, Brown Robert D, Roubin Gary S, Howard Virginia J, Cesko Eldina, Barrett Kevin M, Longbottom Mary E, Voeks Jenifer H, Chaturvedi Seemant, Brott Thomas G, Lal Brajesh K, Meschia James F, Howard George
From the Department of Neurology, Mayo Clinic, Phoenix, AZ (B.M.D.); Department of Neurology, Mayo Clinic, Rochester, MN (R.D.B.); Department of Cardiology, Brookwood Medical Center, Birmingham, AL (G.S.R.); Department of Epidemiology, University of Alabama, Birmingham (V.J.H.); Department of Neurology, Mayo Clinic, Jacksonville, FL (E.C., K.M.B., M.E.L., T.G.B., J.F.M.); Department of Neurology, Medical University of South Carolina, Charleston (J.H.V.); Department of Neurology and Stroke Program, University of Miami Miller School of Medicine, FL (S.C.); Department of Surgery, University of Maryland, Baltimore (B.K.L.); and Department of Biostatistics, University of Alabama at Birmingham (G.H.).
Stroke. 2017 Sep;48(9):2511-2518. doi: 10.1161/STROKEAHA.117.016976. Epub 2017 Aug 2.
Multicenter clinical trials attempt to select sites that can move rapidly to randomization and enroll sufficient numbers of patients. However, there are few assessments of the success of site selection.
In the CREST-2 (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trials), we assess factors associated with the time between site selection and authorization to randomize, the time between authorization to randomize and the first randomization, and the average number of randomizations per site per month. Potential factors included characteristics of the site, specialty of the principal investigator, and site type.
For 147 sites, the median time between site selection to authorization to randomize was 9.9 months (interquartile range, 7.7, 12.4), and factors associated with early site activation were not identified. The median time between authorization to randomize and a randomization was 4.6 months (interquartile range, 2.6, 10.5). Sites with authorization to randomize in only the carotid endarterectomy study were slower to randomize, and other factors examined were not significantly associated with time-to-randomization. The recruitment rate was 0.26 (95% confidence interval, 0.23-0.28) patients per site per month. By univariate analysis, factors associated with faster recruitment were authorization to randomize in both trials, principal investigator specialties of interventional radiology and cardiology, pre-trial reported performance >50 carotid angioplasty and stenting procedures per year, status in the top half of recruitment in the CREST trial, and classification as a private health facility. Participation in StrokeNet was associated with slower recruitment as compared with the non-StrokeNet sites.
Overall, selection of sites with high enrollment rates will likely require customization to align the sites selected to the factor under study in the trial.
URL: http://www.clinicaltrials.gov. Unique identifier: NCT02089217.
多中心临床试验试图选择能够迅速进入随机分组阶段并招募足够数量患者的研究点。然而,对研究点选择的成功情况评估较少。
在CREST - 2(无症状性颈动脉狭窄的颈动脉血运重建与药物治疗试验)中,我们评估了与研究点选择至随机分组授权之间的时间、随机分组授权至首次随机分组之间的时间以及每个研究点每月的平均随机分组数量相关的因素。潜在因素包括研究点的特征、主要研究者的专业以及研究点类型。
对于147个研究点,研究点选择至随机分组授权之间的中位时间为9.9个月(四分位间距,7.7,12.4),未发现与研究点早期启动相关的因素。随机分组授权至随机分组之间的中位时间为4.6个月(四分位间距,2.6,10.5)。仅在颈动脉内膜切除术研究中有随机分组授权的研究点随机分组速度较慢,所检查的其他因素与随机分组时间无显著关联。招募率为每个研究点每月0.26例患者(95%置信区间,0.23 - 0.28)。通过单因素分析,与更快招募相关的因素包括在两项试验中均有随机分组授权、介入放射学和心脏病学的主要研究者专业、试验前报告每年进行>50例颈动脉血管成形术和支架置入术、在CREST试验中招募处于前半部分、以及被分类为私立医疗机构。与非StrokeNet研究点相比,参与StrokeNet与招募速度较慢相关。
总体而言,选择高入组率的研究点可能需要根据试验中所研究的因素进行定制,以使所选研究点与之匹配。